3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
34
Neoplasm Metastasis
7
Neoplasms
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms, Male
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Metastatic Breast Cancer With Intracranial Metastases
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Her2 Positive Metastatic Breast Cancer
1
Head and Neck Neoplasms
1
HER2 Positive Esophagogastric Cancer
1
GastroEsophageal Cancer
1
Esophageal Squamous Cell Carcinoma
1
Diarrhea
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Ductal, Breast
1
Carcinoma
1
Breast Diseases
1
Brain Neoplasms
1
Interventions
ixabepilone
2
aldesleukin
2
Oxaliplatin
2
sargramostim
1
rF-B7.1 vaccine
1
peginterferon alfa-2b
1
indolepropanol phosphate
1
fludarabine phosphate
1
birinapant
1
becatecarin
1
alvocidib
1
Topotecan
1
Sorafenib
1
Pharmacogenomic Testing
1
Peripheral Blood Stem Cell Transplantation
1
O(6)-benzylguanine
1
Nitroarginine
1
Methods
1
Magnetic Resonance Spectroscopy
1
Lapatinib
1
Interleukin-2
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Early Intervention, Educational
1
Docetaxel
1
Decitabine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Unspecified Adult Solid Tumor, Protocol Specific
×
Lapatinib
×
Clear all
NCT00804310
2012-03-28
UCDCC#207
University of California, Davis
Phase 1
Terminated
5 enrolled